相关实验视频

Updated: Sep 9, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

一种针对COX-2-的产药在膀癌模型中诱导细胞亡并减少炎症

Ya Li¹, Siyang Liu², Meng Zhou¹

¹Department of Urology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing 210008, China.

Pharmaceuticals (Basel, Switzerland)

|August 28, 2025

概括

一种新的白金 (IV) 前药,DNP,结合了化疗和膀癌的抗炎作用. 在临床前模型中,DNP表现出优异的细胞毒性,并减少了瘤生长和炎症.

科学领域:

癌症学
药理学
生物化学

背景情况:

膀癌是一种普遍且复杂的恶性瘤.
传统的化疗 (cisplatin) 面临严重的副作用和耐药性等挑战.
一种新的白金 (IV) 前药,DNP,被开发为提供西斯和纳素,一种抗炎药物.

研究的目的:

调查新 (IV) 前药DNP在膀癌中的治疗潜力.
评估DNP的细胞毒性和抗炎药物的双重作用.
在临床前的膀癌模型中评估DNP的疗效.

主要方法:

使用二维和三维膀癌细胞模型评估了DNP的细胞毒性.
转录组分析 (RNA-seq) 确定了DNP调节的亡和炎症途径.
在实验室中对抗炎症效果和体内抗瘤效果进行了评估.

主要成果:

与西斯普拉丁 (CDDP) 相比,DNP显示细胞内积增加和细胞毒性增加.
在膀癌模型中,DNP有效抑制了瘤的扩散和诱导的亡.
在体内,DNP表现出显著的抗炎作用并抑制瘤生长.

结论:

通过提供细胞毒性和抗炎成分,DNP具有双重抗瘤活性.
新型前药DNP为膀癌提供了一个有前途的治疗策略.
通过增强药物输送和减少炎症,DNP克服了传统化疗的局限性.

关键词:

在 DNP 第四部分膀癌症循环氧化酶-2 (COX-2) 的使用纳素 (NPX)

更多相关视频

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...